Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab to Mitigate Cardiovascular Risk in RA Patients
NCT01893996Phase 4Completed
- Sponsor
- Jonathan Graf
- Start
- Jul 2013
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Jonathan Graf. Primary endpoint: Change in Endothelial Cell Function as detected by brachial artery FMD at 78 weeks. Started Jul 2013; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01893996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01893996.